Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$0.77
$0.77
$0.67
$3.77
$3.37M1.12N/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.05
+7.8%
$0.08
$0.04
$51.50
$498K1.691.32 million shs80,898 shs
Organovo Holdings, Inc. stock logo
ONVO
Organovo
$3.94
$1.56
$21.96
$3.47M1.13617,505 shs243,634 shs
SciSparc Ltd. stock logo
SPRC
SciSparc
$7.66
+1.5%
$6.71
$4.14
$37.59
$4.06M0.72190,030 shs31,010 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00%0.00%0.00%0.00%-5.11%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.00%-29.50%-47.13%-84.33%-99.92%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
0.00%0.00%0.00%+16.57%-71.24%
SciSparc Ltd. stock logo
SPRC
SciSparc
0.00%+7.87%+21.30%+31.52%-44.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.1588 of 5 stars
0.03.00.00.00.00.00.6
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/AN/AN/AN/AN/AN/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
0.479 of 5 stars
0.05.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00
N/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.00
N/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
0.00
N/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$7.66M0.44N/AN/A$0.25 per share3.06
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/A$1.29 per shareN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
$122K0.00N/AN/A$0.02 per share0.00
SciSparc Ltd. stock logo
SPRC
SciSparc
$1.31M3.10N/AN/A$18.13 per share0.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
-$7.88MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$48.93M-$219.00N/AN/AN/A-812.56%-207.31%8/11/2025 (Estimated)
Organovo Holdings, Inc. stock logo
ONVO
Organovo
-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%N/A
SciSparc Ltd. stock logo
SPRC
SciSparc
-$6.28MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/AN/AN/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.01
0.88
0.83
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/A
1.30
1.30
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/A
0.72
1.72
SciSparc Ltd. stock logo
SPRC
SciSparc
N/A
5.36
5.28

Institutional Ownership

CompanyInstitutional Ownership
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.63%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
17.24%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
8.23%
SciSparc Ltd. stock logo
SPRC
SciSparc
25.06%

Insider Ownership

CompanyInsider Ownership
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
6.46%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.06%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
3.72%
SciSparc Ltd. stock logo
SPRC
SciSparc
1.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
504.41 million4.53 millionOptionable
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
2010.93 million6.63 millionNo Data
Organovo Holdings, Inc. stock logo
ONVO
Organovo
201.70 million14.79 millionOptionable
SciSparc Ltd. stock logo
SPRC
SciSparc
4530,000527,000Not Optionable

Recent News About These Companies

SciSparc (NASDAQ:SPRC) Trading Up 10.2% - What's Next?
SciSparc Announces 1-for-21 Reverse Share Split
SciSparc announces collaboration with Clearmind Medicine
SciSparc files to sell 61.21M ordinary shares for holders

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Genetic Technologies stock logo

Genetic Technologies NASDAQ:GENE

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Hepion Pharmaceuticals stock logo

Hepion Pharmaceuticals NASDAQ:HEPA

$0.05 +0.00 (+7.80%)
As of 10:03 AM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Organovo stock logo

Organovo NASDAQ:ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

SciSparc stock logo

SciSparc NASDAQ:SPRC

$7.66 +0.12 (+1.53%)
As of 10:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.